Feature | Heart Valve Technology | March 14, 2017

Conscious Sedation TAVR Reduced Length-of-Stay and Hospital Costs

Minneapolis Heart Institute Foundation quality improvement review reduced LOS and cost without affecting the safety and outcomes of the procedure

TAVR, TAVI, conscience sedation

March 14, 2017 — Transcatheter aortic valve replacement (TAVR) for aortic stenosis continues to evolve with the adoption of methods intended to maximize efficacy, safety and patient recovery. Researchers at the Valve Science Center at Minneapolis Heart Institute Foundation recently conducted quality improvement review to examine the impact of the use of minimal anesthesia with conscious sedation (CS) in patients with severe, symptomatic aortic stenosis (AS) undergoing TAVR.
 
Using a multidisciplinary collaboration, a program was initiated to perform transfemoral TAVR with CS to treat patients with native valve AS.  Clinical outcomes for the first 50 patients treated with CS were compared to 50 control patients who had undergone TAVR with general anesthesia (GA) immediately preceding CS implementation. The two patient groups were similar with respect to age, hemodynamic severity of AS, symptom status and frailty. However, in comparison to GA patients, those who had TAVR with CS had shorter median procedure time and hospital length-of-stay (LOS). Procedural success with TAVR and major adverse complications were similar between the groups.  Overall, implementation of TAVR with CS led to a $2,833 reduction in median total variable costs per treated patient. Researchers concluded the implementation of a multidisciplinary program that enabled TAVR to be performed with CS led to significant reductions in LOS and hospital costs, without affecting the effectiveness and safety of the procedure.
 
“The evidence and insight gathered in this analysis supports a novel shift in how we manage our transfemoral TAVR patient population going forward,”  said Marcus Burns, DNP, principal investigator at the Minneapolis Heart Institute Foundation. “Conscious sedation, with its ability to maximize the ease of recovery from TAVR procedures, is a huge advancement for the many patients afflicted with aortic stenosis who seek treatment at our facility."  To date, researchers at the Valve Science Center at Minneapolis Heart Institute Foundation have performed more than 120 conscious sedation TF-TAVR’s since February 2016. “While interest in using conscious sedation for TAVR is steadily growing and a majority of centers have not yet adopted or just are beginning to adopt this approach in its true form," Burns explained.
 
The researchers will present their results at the American College of Cardiology (ACC) annual scientific session and expo this month.

 

Related Content for Conscious Sedadtion and TAVR:

VIDEO: Conscious Sedation for TAVR Procedures

Moderate Sedation Shows Promise for TAVR Patients

VIDEO: The State of TAVR in 2016

Michigan Hospital Employing Conscious Sedation for Aortic Aneurysm Repair

Moderate Sedation Shows Promise for TAVR Patients

UTHealth, Memorial Hermann Perform Conscious Sedation TAVR Procedure

 

 


Related Content

News | Heart Valve Technology

Dec. 26, 2025 — Edwards Lifesciences has announced the company’s SAPIEN M3 mitral valve replacement system, a ...

Home December 24, 2025
Home
News | Heart Valve Technology

Nov. 17, 2025 — Royal Philips has introduced DeviceGuide, an AI-powered device tracking* solution that assists ...

Home November 17, 2025
Home
News | Heart Valve Technology | Cedars-Sinai Medical Center

Oct. 28, 2025 — People who underwent a minimally invasive procedure to have their heart’s aortic valve replaced had ...

Home October 29, 2025
Home
News | Heart Valve Technology

Aug. 28, 2025 — Medtronic plc has announced it received U.S. Food and Drug Administration (FDA) approval for the ...

Home August 29, 2025
Home
News | Heart Valve Technology

Aug. 18, 2025 — A new study published in The Annals of Thoracic Surgery, a journal from The Society of Thoracic Surgeons ...

Home August 19, 2025
Home
News | Heart Valve Technology

Aug. 4, 2025 — Corcym announced that its Perceval Plus sutureless aortic heart valve was used in a first-ever robotic ...

Home August 05, 2025
Home
News | Heart Valve Technology

July 10, 2025 — On July 2, 2025, Centers for Medicare & Medicaid Services (CMS) issued a National Coverage Determination ...

Home July 11, 2025
Home
News | Heart Valve Technology

June 27, 2025 – Foldax Inc., a leader in the development of innovative polymer heart valves, has announced compelling ...

Home June 27, 2025
Home
News | Heart Valve Technology

June 04, 2025 — HeartSciences Inc. has announced that the U.S. Food and Drug Administration has granted Breakthrough ...

Home June 12, 2025
Home
News | Heart Valve Technology

May 27, 2025 — Abbott has announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne ...

Home May 28, 2025
Home
Subscribe Now